Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SHY trades at $81.88, down 0.04% with a bearish technical signal from moving averages. The ETF shows neutral momentum oscillators and uniform support/resistance at $82. Recent corporate actions include scheduled dividends of $0.24 per share through mid-2026, providing income stability amid flat price movement.

Outlook remains cautious due to technical bearishness and interest rate sensitivity. Opportunities include consistent dividend yields, while risks involve Federal Reserve policy shifts impacting bond ETFs. Investors should weigh income benefits against potential rate hike volatility in the fixed income sector.